Table 3.
Histologic subtyping of available patient samples and PDX models
| Patient ID | Histology | % epithelioid | |||
|---|---|---|---|---|---|
| Patient | PDX | Patient | PDX | ||
| Non-epithelioid | MSK_LX362 | Biphasic | NA | 50 | NA |
| MSK_LX759 | Biphasic | Epithelioid | 90 | 100 | |
| MSK_LX307 | Biphasic | Biphasic | 10 | 90 | |
| MSK_LX175 | Biphasic | Biphasic | 70 | 80 | |
| MSK_LX651 | Biphasic | Epithelioid | 90 | 100 | |
| MSK_LX707 | Sarcomatoid | NA | 0 | NA | |
| MSK_LX866A | Sarcomatoid | Sarcomatoid | 0 | 0 | |
Comparative histologic subtyping for the patient (n = 22) and PDX TMA samples (n = 16) with available tissue. For the 7 patient samples with non-epithelioid histology the percent epithelioid cells were annotated and compared to the 5 available PDX specimens. E epithelioid, B biphasic, S sarcomatoid, PDX patient derived xenograft, MSKCC Memorial Sloan Kettering Cancer Center, Trabecular [T]; Tubulopapillary [TP]; Solid [S]; Micropapillary [MP]; Pleomorphic [P]; not applicable [NA]